Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
Nexgel Inc (NXGL) specializes in advanced hydrogel solutions for medical, cosmetic, and diagnostic applications through proprietary electron beam cross-linking technology. This page provides centralized access to official corporate announcements and strategic developments.
Investors and industry professionals will find verified updates including earnings reports, product launch details, regulatory milestones, and partnership announcements. Our curated news collection enables efficient tracking of NXGL's innovations in transdermal drug delivery systems and FDA-approved wound care solutions.
Key content categories include:
- Financial performance updates and SEC filings
- New hydrogel product releases across medical and consumer markets
- Manufacturing process innovations and patent developments
- Strategic collaborations in healthcare and cosmetics sectors
Bookmark this page for real-time access to NXGL's corporate communications and market-moving announcements. For comprehensive analysis of hydrogel industry trends, visit Stock Titan's research portal regularly.
NEXGEL (NASDAQ: NXGL), a specialist in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, has announced its participation in the upcoming Planet MicroCap Showcase: Vegas 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Wednesday, April 23, 2025, at 9:30 a.m. PT in Track 4 - Loire at the Paris Hotel & Casino, Las Vegas. The event runs from April 22-24, 2025.
Investors interested in one-on-one meetings with Mr. Levy can arrange appointments through Planet Micro representatives or by contacting KCSA Strategic Communications at NEXGEL@KCSA.Com. A webcast of the presentation will be available through the company's investor relations website.
NEXGEL (NASDAQ: NXGL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $3.04 million, up 181% year-over-year, while full-year revenue hit $8.69 million, increasing 112% compared to 2023.
Key Q4 metrics include gross profit of $1.13 million (37.2% margin) and net loss of $0.85 million. Full-year 2024 showed gross profit of $2.75 million (31.6% margin) with a net loss of $3.28 million. The company achieved over 100% revenue growth for the third consecutive year.
Notable developments include first shipments of SilverSeal® to Cintas, successful growth of the Silly George brand from $2M to $5M+ annual revenue, and partnership with STADA to launch Histasolv in North America. The company projects 2025 revenue guidance of $13 million and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 24, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone at 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International). A replay will be available through April 3, 2025, accessible at 1-844-512-3921 (U.S.) or 1-412-317-6671 (International) using code 11158402. A webcast replay will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Tuesday, March 25th, 2025, at 9:30 a.m. ET. The two-day conference will take place on March 25-26, 2025, and interested parties can access the webcast through the provided link.
Investors seeking one-on-one meetings with Mr. Levy can arrange appointments through iAccess representatives or by contacting KCSA Strategic Communications.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and over-the-counter products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming Webull Consumer Virtual Webinar. The company's Chief Executive Officer, Adam Levy, will deliver a presentation on February 18, 2025, at 2:40 p.m. ET.
Investors interested in attending can access the webinar through the provided Webull zoom registration link. For those seeking one-on-one meetings with CEO Adam Levy, arrangements can be made through Webull representatives or by contacting KCSA Strategic Communications via email at NEXGEL@KCSA.Com.
NEXGEL (NASDAQ: NXGL) released its shareholder letter and guidance for 2024-2025, projecting Q4 2024 revenue of approximately $3.0 million and full-year 2024 revenue of $8.6 million, marking over 100% growth year-over-year for the third consecutive year. The company expects to generate at least $13 million in revenue for 2025 and achieve positive cash flow from operations.
The company operates in three core segments: contract manufacturing and white label, consumer products, and medical device development. Their consumer products division saw significant growth in 2024, particularly with the Silly George acquisition growing from $2 million to over $5 million in annual revenue. The company's partnership with Stada is progressing well, with their first product Histasolv exceeding projections and two additional product launches expected in H2 2025.
NEXGEL (NASDAQ: NXGL) has appointed Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. McGuire, who brings over 30 years of financial and public company experience, has been consulting with NEXGEL since September 2, 2024. He previously served as CFO for several private and public companies in healthcare, financial services, and manufacturing sectors, and was instrumental in guiding a biotech company to NYSE listing in July 2022.
The current CFO, Adam E. Drapczuk III, will transition to a consulting role with the company through his firm, Achieving Consulting Excellence, McGuire, a former Price Waterhouse CPA and Notre Dame graduate, will lead NEXGEL's finance functions as part of the executive management team. The appointment comes as NEXGEL, a provider of medical and OTC hydrogel products, continues to experience high growth.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Winter Conference 2024.
Chief Executive Officer Adam Levy will deliver a presentation on Tuesday, December 10th at 10:30 a.m. ET. The two-day conference will take place on December 10-11, 2024. Interested parties can access the webcast presentation through the provided link, and one-on-one investor meetings can be arranged through iAccess representatives or KCSA Strategic Communications.
NEXGEL reported record Q3 2024 revenue of $2.94 million, marking a 141% year-over-year and 104% sequential increase. The growth was driven by approximately 100% sequential increases in both branded consumer products and contract manufacturing. Gross profit margin improved to 43.6% from 28.2% in Q3 2023. The company reported a net loss of $754,000 and an Adjusted EBITDA loss of $347,000. Cash balance stood at $1.10 million, with an additional $2 million raised through a registered direct offering post-quarter.
NEXGEL (NASDAQ: NXGL) announced a $2 million registered direct offering, issuing 727,272 common stock shares at $2.75 per share, along with warrants to purchase 363,636 additional shares at $4.25 per share. The warrants are immediately exercisable with a five-year term. Company insiders, including management and Board members, participated in the offering with a six-month lock-up period. The funds will be used to increase inventory and marketing for Silly George, support receivables from new large customer orders, and pursue acquisition opportunities.